feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Business and Economy / LIC Boosts Sun Pharma Stake Past 5%

LIC Boosts Sun Pharma Stake Past 5%

14 Jan

•

Summary

  • LIC increased its Sun Pharma holding to over 5% on January 14.
  • LIC acquired 2,02,500 additional shares on January 13.
  • Sun Pharma invested ₹1685.5 crore in research and development.
LIC Boosts Sun Pharma Stake Past 5%

Life Insurance Corporation of India (LIC) has increased its stake in Sun Pharma, crossing the 5% ownership mark. As of January 14, LIC's shareholding in the prominent pharmaceutical company now stands at 5.004%, up from 4.996%. This acquisition of 2,02,500 shares on January 13 underscores LIC's significant presence as a major institutional investor.

Sun Pharma's stock has demonstrated strong long-term performance, rallying significantly over the past five and ten years. The company's dedication to innovation is further evidenced by its substantial investment of ₹1685.5 crore in research and development, accounting for 6% of its total sales.

Management highlighted that growth was primarily led by India, emerging markets, and the rest of the world. Notably, US sales of innovative medicines have now surpassed generics for the company during the recent quarter. Sun Pharma remains focused on portfolio expansion and enhancing its execution capabilities.

This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
trending

Afghan student found dead at MSU

trending

KNRUHS scraps maternity fee

trending

IIT JAM 2026 admit card

trending

Blinkit ends 10-minute delivery

trending

SBI Clerk Mains Result Soon

trending

Michigan State vs Indiana

trending

Tata Punch facelift launched

trending

Gujarat Giants vs Mumbai Indians

trending

Delhi takes on Vidarbha

Disclaimer:
LIC's stake in Sun Pharma is currently over 5%, specifically 5.004% as of January 14.
Sun Pharma invested ₹1685.5 crore in research and development, which is 6% of its total sales.
Sun Pharma's growth is led by India, emerging markets, and the rest of the world, with US innovative medicine sales surpassing generics.

Read more news on

Business and Economyside-arrow

You may also like

Canara HSBC: Buy Signal for Growth in Life Insurance

3 hours ago • 4 reads

article image

India's Insurance Dip: Premiums Rise, Penetration Falls

1 Jan • 55 reads

article image

India Life Insurers Surge in November Growth

9 Dec, 2025 • 130 reads

article image

FM Clarifies LIC Investment Independence

1 Dec, 2025 • 178 reads

article image

LIC Bounces Back After Pandemic Slump, Aims for Strong Finish

16 Nov, 2025 • 210 reads

article image